|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC2A4RG |
Gene summary for SLC2A4RG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC2A4RG | Gene ID | 56731 |
| Gene name | SLC2A4 regulator | |
| Gene Alias | GEF | |
| Cytomap | 20q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9NR83 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56731 | SLC2A4RG | GSM4909281 | Human | Breast | IDC | 2.89e-04 | 2.40e-01 | 0.21 |
| 56731 | SLC2A4RG | GSM4909282 | Human | Breast | IDC | 3.14e-02 | 2.24e-01 | -0.0288 |
| 56731 | SLC2A4RG | GSM4909293 | Human | Breast | IDC | 5.25e-24 | 4.69e-01 | 0.1581 |
| 56731 | SLC2A4RG | GSM4909298 | Human | Breast | IDC | 5.71e-04 | 2.50e-01 | 0.1551 |
| 56731 | SLC2A4RG | GSM4909304 | Human | Breast | IDC | 1.34e-20 | 4.90e-01 | 0.1636 |
| 56731 | SLC2A4RG | GSM4909311 | Human | Breast | IDC | 1.55e-04 | 8.34e-02 | 0.1534 |
| 56731 | SLC2A4RG | GSM4909317 | Human | Breast | IDC | 1.13e-07 | 3.46e-01 | 0.1355 |
| 56731 | SLC2A4RG | GSM4909318 | Human | Breast | IDC | 7.47e-08 | 7.94e-01 | 0.2031 |
| 56731 | SLC2A4RG | GSM4909319 | Human | Breast | IDC | 1.88e-14 | 1.46e-01 | 0.1563 |
| 56731 | SLC2A4RG | GSM4909321 | Human | Breast | IDC | 3.39e-03 | 1.91e-01 | 0.1559 |
| 56731 | SLC2A4RG | M2 | Human | Breast | IDC | 4.58e-06 | 6.41e-01 | 0.21 |
| 56731 | SLC2A4RG | DCIS2 | Human | Breast | DCIS | 4.22e-29 | 8.67e-02 | 0.0085 |
| 56731 | SLC2A4RG | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.68e-03 | 1.48e-01 | -0.1808 |
| 56731 | SLC2A4RG | HTA11_347_2000001011 | Human | Colorectum | AD | 2.60e-05 | 1.91e-01 | -0.1954 |
| 56731 | SLC2A4RG | HTA11_696_2000001011 | Human | Colorectum | AD | 8.34e-05 | 1.88e-01 | -0.1464 |
| 56731 | SLC2A4RG | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.92e-03 | 1.85e-01 | -0.059 |
| 56731 | SLC2A4RG | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.78e-03 | 2.86e-01 | 0.0528 |
| 56731 | SLC2A4RG | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.76e-08 | 2.35e-01 | 0.0674 |
| 56731 | SLC2A4RG | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.14e-29 | 7.18e-01 | 0.3859 |
| 56731 | SLC2A4RG | HTA11_99999974143_84620 | Human | Colorectum | MSS | 9.49e-11 | 3.17e-01 | 0.3005 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC2A4RG | SNV | Missense_Mutation | c.293N>C | p.Gly98Ala | p.G98A | Q9NR83 | protein_coding | tolerated(0.32) | probably_damaging(0.949) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| SLC2A4RG | SNV | Missense_Mutation | c.1150C>G | p.Arg384Gly | p.R384G | Q9NR83 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SLC2A4RG | SNV | Missense_Mutation | rs369712293 | c.1105N>T | p.Arg369Trp | p.R369W | Q9NR83 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| SLC2A4RG | SNV | Missense_Mutation | novel | c.478G>C | p.Asp160His | p.D160H | Q9NR83 | protein_coding | deleterious(0.01) | possibly_damaging(0.825) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| SLC2A4RG | SNV | Missense_Mutation | novel | c.455G>A | p.Ser152Asn | p.S152N | Q9NR83 | protein_coding | tolerated(0.16) | benign(0.015) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC2A4RG | SNV | Missense_Mutation | c.512N>T | p.Pro171Leu | p.P171L | Q9NR83 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| SLC2A4RG | SNV | Missense_Mutation | novel | c.1090N>C | p.Tyr364His | p.Y364H | Q9NR83 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC2A4RG | SNV | Missense_Mutation | novel | c.752A>G | p.Asp251Gly | p.D251G | Q9NR83 | protein_coding | deleterious(0) | possibly_damaging(0.805) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| SLC2A4RG | SNV | Missense_Mutation | rs773201767 | c.755N>T | p.Thr252Met | p.T252M | Q9NR83 | protein_coding | deleterious(0.04) | benign(0.01) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC2A4RG | SNV | Missense_Mutation | c.490N>A | p.Asp164Asn | p.D164N | Q9NR83 | protein_coding | deleterious(0.01) | possibly_damaging(0.814) | TCGA-05-4426-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |